Cargando…

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial

Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Marc, Iyer, Deepa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285947/ https://www.ncbi.nlm.nih.gov/pubmed/24894120 http://dx.doi.org/10.1111/1755-5922.12083

Ejemplares similares

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

Dual antiplatelet agents and Rivaroxaban for massive intracoronary thrombus in STEMI
por: Jamal, Nasiruddin, et al.
Publicado: (2015)

Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022)

Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy
por: Makrides, Constantinos Andreas
Publicado: (2016)

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
por: Husted, Steen, et al.
Publicado: (2016)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome
por: Verdoia, Monica, et al.
Publicado: (2021)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement
por: Cohen, Marc
Publicado: (2009)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores
por: Aragam, Krishna G., et al.
Publicado: (2009)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
por: Guo, Yong-zhe, et al.
Publicado: (2021)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Dual antiplatelet treatment after coronary artery bypass surgery
por: Lopez Menendez, Jose, et al.
Publicado: (2015)

Dual antiplatelet therapy for secondary prevention of coronary artery disease
por: Degrauwe, Sophie, et al.
Publicado: (2017)

Optimal duration of dual antiplatelet therapy for coronary artery disease
por: Kikkert, W. J., et al.
Publicado: (2018)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
por: Xu, Haiyan, et al.
Publicado: (2016)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Evaluate the Correlation between the TIMI Frame Count, IMR, and CFR in Coronary Microvascular Disease
por: Xu, Xinye, et al.
Publicado: (2022)

Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks
por: Zhang, Yong, et al.
Publicado: (2023)

Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
por: Magnani, Giulia, et al.
Publicado: (2023)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions
por: Huo, SiYan, et al.
Publicado: (2023)

International patterns of dual antiplatelet therapy duration after acute coronary syndromes
por: Bueno, Héctor, et al.
Publicado: (2017)

Effect of acute coronary syndrome patients’ education on adherence to dual antiplatelet therapy
por: El-Toukhy, Hassan, et al.
Publicado: (2017)

Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes
por: Lesiak, Maciej, et al.
Publicado: (2021)

Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
por: Tung, Ying-Chang, et al.
Publicado: (2020)

Correlation of increased corrected TIMI frame counts and the topographical extent of isolated coronary artery ectasia
por: Wu, Wei, et al.
Publicado: (2018)

Association between High Lipid Burden of Target Lesion and Slow TIMI Flow in Coronary Interventions
por: Lim, Subin, et al.
Publicado: (2022)

HEART and TIMI Scores Predict Severe Coronary Atherosclerosis in Patients With End-Stage Renal Disease
por: Parikh, Trishna B, et al.
Publicado: (2023)

Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study
por: Arbel, Yaron, et al.
Publicado: (2021)

BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding
por: Pan, ChangE, et al.
Publicado: (2012)

Dual antiplatelet therapy and newer agents: More efficacy but lets keep the brain safe!!
por: Bhatia, Rohit, et al.
Publicado: (2015)

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
por: Tayeb, Hussam M, et al.
Publicado: (2010)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qj83arigmqfcbv7oruv2gvitm8